219 related articles for article (PubMed ID: 7640151)
1. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
2. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Madsen H; Hansen TS; Brøsen K
Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
[TBL] [Abstract][Full Text] [Related]
3. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
4. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
5. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
6. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
Koyama E; Sohn DR; Shin SG; Chiba K; Shin JG; Kim YH; Echizen H; Ishizaki T
J Pharmacol Exp Ther; 1994 Nov; 271(2):860-7. PubMed ID: 7965806
[TBL] [Abstract][Full Text] [Related]
7. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
8. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
Bock KW; Schrenk D; Forster A; Griese EU; Mörike K; Brockmeier D; Eichelbaum M
Pharmacogenetics; 1994 Aug; 4(4):209-18. PubMed ID: 7987405
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
10. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
11. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotype determination in the Danish population.
Brøsen K; Nielsen PN; Brusgaard K; Gram LF; Skjødt K
Eur J Clin Pharmacol; 1994; 47(3):221-5. PubMed ID: 7867674
[TBL] [Abstract][Full Text] [Related]
13. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
[TBL] [Abstract][Full Text] [Related]
14. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
15. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
Brøsen K; Skjelbo E; Flachs H
Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
[TBL] [Abstract][Full Text] [Related]
16. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4.
Madsen H; Rasmussen BB; Brøsen K
Clin Pharmacol Ther; 1997 Mar; 61(3):319-24. PubMed ID: 9084457
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
19. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
20. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
Brøsen K
Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]